347 related articles for article (PubMed ID: 26771811)
1. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
2.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Stem Cell Investig; 2016; 3():50. PubMed ID: 27777939
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
[TBL] [Abstract][Full Text] [Related]
4. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
[TBL] [Abstract][Full Text] [Related]
6. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
Patnaik MM; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Knudson RA; Ketterling RP; Tefferi A; Solary E
Leukemia; 2014 Nov; 28(11):2206-12. PubMed ID: 24695057
[TBL] [Abstract][Full Text] [Related]
7. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
[TBL] [Abstract][Full Text] [Related]
9. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
10. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jan; 92(1):56-61. PubMed ID: 27733013
[TBL] [Abstract][Full Text] [Related]
12. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
[TBL] [Abstract][Full Text] [Related]
13. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
14. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
[TBL] [Abstract][Full Text] [Related]
15. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
16. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
17. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
[TBL] [Abstract][Full Text] [Related]
20. Invariant phenotype and molecular association of biallelic
Awada H; Nagata Y; Goyal A; Asad MF; Patel B; Hirsch CM; Kuzmanovic T; Guan Y; Przychodzen BP; Aly M; Adema V; Shen W; Williams L; Nazha A; Abazeed ME; Sekeres MA; Radivoyevitch T; Haferlach T; Jha BK; Visconte V; Maciejewski JP
Blood Adv; 2019 Feb; 3(3):339-349. PubMed ID: 30709865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
